Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cannabis sativa L. 'Afina' is a standardized medical cannabis cultivar specifically developed for administration via the Syqe Inhaler, a proprietary metered-dose aerosol delivery system. Developed by Syqe Medical, this botanical product is designed to provide precise and consistent dosing of cannabinoids, primarily delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which are the main active constituents of the 'Afina' strain. The drug is currently being evaluated in Phase IV clinical trials as an add-on therapy for diabetic peripheral neuropathic pain. The Syqe Inhaler technology utilizes thermal decarboxylation of the raw plant material to generate an aerosol, facilitating rapid pulmonary absorption and high bioavailability while minimizing the variability and side effects associated with traditional cannabis consumption methods.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cannabis sativa L. 'Afina'.